Literature DB >> 23988911

p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.

Jun Zhang1, Christopher S Seet, Clare Sun, Jing Li, Dewen You, Andrew Volk, Peter Breslin, Xingyu Li, Wei Wei, Zhijian Qian, Nancy J Zeleznik-Le, Zhou Zhang, Jiwang Zhang.   

Abstract

MLL (mixed-lineage leukemia)-fusion genes induce the development of leukemia through deregulation of normal MLL target genes, such as HOXA9 and MEIS1. Both HOXA9 and MEIS1 are required for MLL-fusion gene-induced leukemogenesis. Co-expression of HOXA9 and MEIS1 induces acute myeloid leukemia (AML) similar to that seen in mice in which MLL-fusion genes are over-expressed. p27(kip1) (p27 hereafter), a negative regulator of the cell cycle, has also been defined as an MLL target, the expression of which is up-regulated in MLL leukemic cells (LCs). To investigate whether p27 plays a role in the pathogenesis of MLL-leukemia, we examined the effects of p27 deletion (p27(-/-)) on MLL-AF9 (MA9)-induced murine AML development. HOXA9/MEIS1 (H/M)-induced, p27 wild-type (p27(+/+)) and p27(-/-) AML were studied in parallel as controls. We found that LCs from both MA9-AML and H/M-AML can be separated into three fractions, a CD117(-)CD11b(hi) differentiated fraction as well as CD117(+)CD11b(hi) and CD117(+)CD11b(lo), two less differentiated fractions. The CD117(+)CD11b(lo) fraction, comprising only 1-3% of total LCs, expresses higher levels of early hematopoietic progenitor markers but lower levels of mature myeloid cell markers compared to other populations of LCs. p27 is expressed and is required for maintaining the quiescent and drug-resistant states of the CD117(+)CD11b(lo) fraction of MA9-LCs but not of H/M-LCs. p27 deletion significantly compromises the leukemogenic capacity of CD117(+)CD11b(lo) MA9-LCs by reducing the frequency of leukemic stem cells (LSCs) but does not do so in H/M-LCs. In addition, we found that p27 is highly expressed and required for cell cycle arrest in the CD117(-)CD11b(hi) fraction in both types of LCs. Furthermore, we found that c-Myc expression is required for maintaining LCs in an undifferentiated state independently of proliferation. We concluded that p27 represses the proliferation of LCs, which is specifically required for maintaining the quiescent and drug-resistant states of a small subset of MA9-LSCs in collaboration with the differentiation blockage function of c-Myc. Published by Elsevier B.V.

Entities:  

Keywords:  Leukemia stem cell; MLL-leukemia; Quiescence; p27(kip1)

Mesh:

Substances:

Year:  2013        PMID: 23988911      PMCID: PMC3898829          DOI: 10.1016/j.molonc.2013.07.011

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  81 in total

1.  Defects in yolk sac hematopoiesis in Mll-null embryos.

Authors:  J L Hess; B D Yu; B Li; R Hanson; S J Korsmeyer
Journal:  Blood       Date:  1997-09-01       Impact factor: 22.113

2.  Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis.

Authors:  Thomas A Milne; Jaehoon Kim; Gang G Wang; Sonja C Stadler; Venkatesha Basrur; Sarah J Whitcomb; Zhanxin Wang; Alexander J Ruthenburg; Kojo S J Elenitoba-Johnson; Robert G Roeder; C David Allis
Journal:  Mol Cell       Date:  2010-06-10       Impact factor: 17.970

Review 3.  Leukemia stem cells and microenvironment: biology and therapeutic targeting.

Authors:  Marina Y Konopleva; Craig T Jordan
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.

Authors:  Zhen-Biao Xia; Relja Popovic; Jing Chen; Catherine Theisler; Tara Stuart; Donna A Santillan; Frank Erfurth; Manuel O Diaz; Nancy J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-16       Impact factor: 11.205

5.  Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes.

Authors:  Ming-Jin Chang; Hongyu Wu; Nicholas J Achille; Mary Rose Reisenauer; Chau-Wen Chou; Nancy J Zeleznik-Le; Charles S Hemenway; Wenzheng Zhang
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

6.  p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.

Authors:  Jun Zhang; Christopher S Seet; Clare Sun; Jing Li; Dewen You; Andrew Volk; Peter Breslin; Xingyu Li; Wei Wei; Zhijian Qian; Nancy J Zeleznik-Le; Zhou Zhang; Jiwang Zhang
Journal:  Mol Oncol       Date:  2013-08-20       Impact factor: 6.603

7.  Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors.

Authors:  Craig D Jude; Leslie Climer; Diyong Xu; Erika Artinger; Jill K Fisher; Patricia Ernst
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

8.  Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice.

Authors:  H Yagi; K Deguchi; A Aono; Y Tani; T Kishimoto; T Komori
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113

Review 9.  Considerations for targeting malignant stem cells in leukemia.

Authors:  Monica L Guzman; Craig T Jordan
Journal:  Cancer Control       Date:  2004 Mar-Apr       Impact factor: 3.302

Review 10.  MLL fusions: pathways to leukemia.

Authors:  Han Liu; Emily H Y Cheng; James J D Hsieh
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

View more
  13 in total

1.  MLL-TET1 fusion protein promotes immortalization of myeloid progenitor cells and leukemia development.

Authors:  Hyeng-Soo Kim; Seung Hwan Oh; Ju-Heon Kim; Jae-Young Kim; Do-Hyung Kim; Soo-Jin Lee; Sang-Un Choi; Kwon Moo Park; Zae Young Ryoo; Tae Sung Park; Sanggyu Lee
Journal:  Haematologica       Date:  2017-08-10       Impact factor: 9.941

2.  Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis.

Authors:  Y Gu; W Zheng; J Zhang; X Gan; X Ma; Z Meng; T Chen; X Lu; Z Wu; W Huang; R Xu
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

3.  Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression.

Authors:  Mark Sellin; Ryan Mack; Matthew C Rhodes; Lei Zhang; Stephanie Berg; Kanak Joshi; Shanhui Liu; Wei Wei; Peter Breslin S J; Peter Larsen; Richard E Taylor; Jiwang Zhang
Journal:  Br J Cancer       Date:  2022-04-14       Impact factor: 9.075

4.  p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.

Authors:  Jun Zhang; Christopher S Seet; Clare Sun; Jing Li; Dewen You; Andrew Volk; Peter Breslin; Xingyu Li; Wei Wei; Zhijian Qian; Nancy J Zeleznik-Le; Zhou Zhang; Jiwang Zhang
Journal:  Mol Oncol       Date:  2013-08-20       Impact factor: 6.603

5.  Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors:  Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

6.  CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27kip1 signaling.

Authors:  Feifei Zhang; Xiaoye Liu; Chiqi Chen; Jun Zhu; Zhuo Yu; Jingjing Xie; Li Xie; Haitao Bai; Yaping Zhang; Xia Fang; Hao Gu; Chun Wang; Wei Weng; Cheng Cheng Zhang; Guo-Qiang Chen; Aibing Liang; Junke Zheng
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

7.  Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.

Authors:  Jing Li; Andrew Volk; Jun Zhang; Joseph Cannova; Shaojun Dai; Caiqin Hao; Chenglong Hu; Jiewen Sun; Yan Xu; Wei Wei; Peter Breslin; Sucha Nand; Jianjun Chen; Ameet Kini; Jiang Zhu; Jiwang Zhang
Journal:  Oncotarget       Date:  2017-01-31

8.  Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway.

Authors:  J Xin; D You; P Breslin; J Li; J Zhang; W Wei; J Cannova; A Volk; R Gutierrez; Y Xiao; A Ni; G Ng; R Schmidt; Z Xia; J Pan; H Chen; M M Patel; P C Kuo; S Nand; A R Kini; J Zhang; J Chen; J Zhu; J Zhang
Journal:  Leukemia       Date:  2016-10-17       Impact factor: 11.528

9.  An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.

Authors:  Ami V Patel; Katherine E Chaney; Kwangmin Choi; David A Largaespada; Ashish R Kumar; Nancy Ratner
Journal:  EBioMedicine       Date:  2016-06-04       Impact factor: 8.143

10.  The nuclear mitotic apparatus protein NuMA controls rDNA transcription and mediates the nucleolar stress response in a p53-independent manner.

Authors:  Swaathi Jayaraman; Shirisha Chittiboyina; Yunfeng Bai; Patricia C Abad; Pierre-Alexandre Vidi; Cynthia V Stauffacher; Sophie A Lelièvre
Journal:  Nucleic Acids Res       Date:  2017-11-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.